Journal
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Publication Date
8-1-2023
Volume
24
Issue
5-6
First Page
523
Last Page
534
Document Type
Open Access Publication
DOI
10.1080/21678421.2023.2216223
Rights and Permissions
Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):523-534. doi: 10.1080/21678421.2023.2216223. © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
Recommended Citation
Shefner, Jeremy M; Miller, Timothy M; and et al., "COURAGE-ALS: A randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success." Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 24, 5-6. 523 - 534. (2023).
https://digitalcommons.wustl.edu/oa_4/2153
Department
ICTS (Institute of Clinical and Translational Sciences)
